New G Lab

New G Lab Pharma is a South Korean biopharmaceutical company focused on developing metabolic anticancer therapies. The company's lead candidate, KAT-001, is a formulation of 2-deoxy-D-glucose (2-DG) designed to inhibit hexokinase 2 and disrupt the glycolytic pathway in cancer cells, leveraging the Warburg effect. Beyond oncology, the company has explored applications for its metabolic inhibitors in viral infections and other metabolic disorders. New G Lab Pharma operates through its headquarters in Korea and a research-focused subsidiary in the United States. The company's approach aims to selectively target malignant cells while sparing healthy tissue by interfering with cancer-specific energy production.